Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus.

NCT03654313 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03654313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03654313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus.
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
September 28, 2018
Completion date
July 21, 2020
Enrollment
88 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, cardiovascular disease